BRAF mutation predicts sensitivity to MEK inhibition

David B. Solit, Levi A. Garraway, Christine Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose M. Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith Sebolt-Leopold, William R. Sellers, Neal Rosen

Research output: Contribution to journalArticle

Abstract

The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members1. Using small-molecule inhibitors of MEK and an integrated genetic and pharmacologic analysis, we find that mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harbouring a RAS mutation. This MEK dependency was observed in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest. Pharmacological MEK inhibition completely abrogated tumour growth in BRAF mutant xenografts, whereas RAS mutant tumours were only partially inhibited. These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype.

Original languageEnglish (US)
Pages (from-to)358-362
Number of pages5
JournalNature
Volume439
Issue number7074
DOIs
StatePublished - Jan 19 2006
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Mutation
Neoplasms
Cyclin D1
Extracellular Signal-Regulated MAP Kinases
Heterografts
Phosphotransferases
Down-Regulation
Pharmacology
Growth
Proteins

ASJC Scopus subject areas

  • General

Cite this

Solit, D. B., Garraway, L. A., Pratilas, C., Sawai, A., Getz, G., Basso, A., ... Rosen, N. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439(7074), 358-362. https://doi.org/10.1038/nature04304

BRAF mutation predicts sensitivity to MEK inhibition. / Solit, David B.; Garraway, Levi A.; Pratilas, Christine; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal.

In: Nature, Vol. 439, No. 7074, 19.01.2006, p. 358-362.

Research output: Contribution to journalArticle

Solit, DB, Garraway, LA, Pratilas, C, Sawai, A, Getz, G, Basso, A, Ye, Q, Lobo, JM, She, Y, Osman, I, Golub, TR, Sebolt-Leopold, J, Sellers, WR & Rosen, N 2006, 'BRAF mutation predicts sensitivity to MEK inhibition', Nature, vol. 439, no. 7074, pp. 358-362. https://doi.org/10.1038/nature04304
Solit DB, Garraway LA, Pratilas C, Sawai A, Getz G, Basso A et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006 Jan 19;439(7074):358-362. https://doi.org/10.1038/nature04304
Solit, David B. ; Garraway, Levi A. ; Pratilas, Christine ; Sawai, Ayana ; Getz, Gad ; Basso, Andrea ; Ye, Qing ; Lobo, Jose M. ; She, Yuhong ; Osman, Iman ; Golub, Todd R. ; Sebolt-Leopold, Judith ; Sellers, William R. ; Rosen, Neal. / BRAF mutation predicts sensitivity to MEK inhibition. In: Nature. 2006 ; Vol. 439, No. 7074. pp. 358-362.
@article{b99ed52ed3f54414a883fd61dffe36b2,
title = "BRAF mutation predicts sensitivity to MEK inhibition",
abstract = "The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members1. Using small-molecule inhibitors of MEK and an integrated genetic and pharmacologic analysis, we find that mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harbouring a RAS mutation. This MEK dependency was observed in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest. Pharmacological MEK inhibition completely abrogated tumour growth in BRAF mutant xenografts, whereas RAS mutant tumours were only partially inhibited. These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype.",
author = "Solit, {David B.} and Garraway, {Levi A.} and Christine Pratilas and Ayana Sawai and Gad Getz and Andrea Basso and Qing Ye and Lobo, {Jose M.} and Yuhong She and Iman Osman and Golub, {Todd R.} and Judith Sebolt-Leopold and Sellers, {William R.} and Neal Rosen",
year = "2006",
month = "1",
day = "19",
doi = "10.1038/nature04304",
language = "English (US)",
volume = "439",
pages = "358--362",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7074",

}

TY - JOUR

T1 - BRAF mutation predicts sensitivity to MEK inhibition

AU - Solit, David B.

AU - Garraway, Levi A.

AU - Pratilas, Christine

AU - Sawai, Ayana

AU - Getz, Gad

AU - Basso, Andrea

AU - Ye, Qing

AU - Lobo, Jose M.

AU - She, Yuhong

AU - Osman, Iman

AU - Golub, Todd R.

AU - Sebolt-Leopold, Judith

AU - Sellers, William R.

AU - Rosen, Neal

PY - 2006/1/19

Y1 - 2006/1/19

N2 - The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members1. Using small-molecule inhibitors of MEK and an integrated genetic and pharmacologic analysis, we find that mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harbouring a RAS mutation. This MEK dependency was observed in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest. Pharmacological MEK inhibition completely abrogated tumour growth in BRAF mutant xenografts, whereas RAS mutant tumours were only partially inhibited. These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype.

AB - The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members1. Using small-molecule inhibitors of MEK and an integrated genetic and pharmacologic analysis, we find that mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harbouring a RAS mutation. This MEK dependency was observed in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest. Pharmacological MEK inhibition completely abrogated tumour growth in BRAF mutant xenografts, whereas RAS mutant tumours were only partially inhibited. These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype.

UR - http://www.scopus.com/inward/record.url?scp=31144453233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31144453233&partnerID=8YFLogxK

U2 - 10.1038/nature04304

DO - 10.1038/nature04304

M3 - Article

VL - 439

SP - 358

EP - 362

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7074

ER -